Figure 4. PRMT5 inhibition induces NF-кB inactivation in bladder cancer. A. shPRMT5 reduced NF-κB activation in T24 cells. B. EPZ015666 decreased NF-κB activation in a dose-dependent manner. C. shPRMT5 reduced NF-κB target genes (BCLXL and c-IAP1) expression. D. EPZ015666 decreased BCLXL and c-IAP1 expression. *P < 0.05 vs. control group. E. EPZ015666 (200 µM) impairs NF-κB enrichment on the BCLXL and c-IAP1 promoters. ChIP was performed using IgG or NF-κB p65 antibody; *, P < 0.05; **, P < 0.01 vs. control.
